A review of health care models for coronary heart disease interventions

被引:18
作者
Cooper K. [1 ]
Brailsford S.C. [2 ]
Davies R. [3 ]
Raftery J. [1 ]
机构
[1] Wessex Institute for Health Research and Development, University of Southampton, Southampton, Hants SO16 7PX, Highfield
[2] School of Management, University of Southampton, Southampton, Hants SO17 1BJ, Highfield
[3] Warwick Business School, Warwick University
关键词
Coronary heart disease; Decision tree; Discrete event simulation; Economic evaluation; Health care; Markov; Model;
D O I
10.1007/s10729-006-9996-x
中图分类号
学科分类号
摘要
This article reviews models for the treatment of coronary heart disease (CHD). Whereas most of the models described were developed to assess the cost effectiveness of different treatment strategies, other models have also been used to extrapolate clinical trials, for capacity and resource planning, or to predict the future population with heart disease. In this paper we investigate the use of modelling techniques in relation to different types of health intervention, and we discuss the assumptions and limitations of these approaches. Many of the models reviewed in this paper use decision tree models for acute or short term interventions, and Markov or state transition models for chronic or long term interventions. Discrete event simulation has, however, been used for more complex whole system models, and for modelling resource-constrained interventions and operational planning. Nearly all of the studies in our review used cohort-based models rather than population based models, and therefore few models could estimate the likely total costs and benefits for a population group. Most studies used de novo purpose built models consisting of only a small number of health states. Models of the whole disease system were less common. The model descriptions were often incomplete. We recommend that the reporting of model structure, assumptions and input parameters is more explicit, to reduce the risk of biased reporting and ensure greater confidence in the model results. © 2006 Springer Science + Business Media, LLC.
引用
收藏
页码:311 / 324
页数:13
相关论文
共 131 条
[91]  
Johannesson M., Jonsson B., Kjekshus J., Olsson A.G., Pedersen T.R., Wedel H., Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease, N Engl J Med, 336, 5, pp. 332-336, (1997)
[92]  
Maclaine G.D., Patel H., A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels, Int J Clin Pract, 55, 4, pp. 243-249, (2001)
[93]  
Muls E., Van Ganse E., Closon M.C., Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: Comparison between Belgium and the United States of a projected risk model, Atherosclerosis, 137, SUPPL., (1998)
[94]  
Palmer S.J., Brady A.J., Ratcliffe A.E., The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS, Int J Clin Pract, 57, 9, pp. 792-800, (2003)
[95]  
Pharoah P.D., Hollingworth W., Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population, BMJ, 312, 7044, pp. 1443-1448, (1996)
[96]  
Pickin D.M., McCabe C.J., Ramsay L.E., Payne N., Haq I.U., Yeo W.W., Jackson P.R., Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug, Heart, 82, 3, pp. 325-332, (1999)
[97]  
Prosser L.A., Stinnett A.A., Goldman P.A., Williams L.W., Hunink M.G., Goldman L., Weinstein M.C., Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics, Ann Intern Med, 132, 10, pp. 769-779, (2000)
[98]  
Russell M.W., Huse D.M., Miller J.D., Kraemer D.F., Hartz S.C., Cost effectiveness of HMG-CoA reductase inhibition in Canada, Can J Clin Pharmacol, 8, 1, pp. 9-16, (2001)
[99]  
Scuffham P.A., Chaplin S., An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK, Pharmacoeconomics, 22, 8, pp. 525-535, (2004)
[100]  
Tsevat J., Kuntz K.M., Orav E.J., Weinstein M.C., Sacks F.M., Goldman L., Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels, Am Heart J, 141, 5, pp. 727-734, (2001)